Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Celecoxib is a nonsteroidal anti-inflammatory drug
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
The company’s largest center for medical device applications, serving the entire Asian market
To streamline complex medical writing workflows with GenAI
Friesland Campina Professional’s innovative Kievit portfolio features fat powders, creamers, foamers, whipping agents, cake emulsifiers
Subscribe To Our Newsletter & Stay Updated